SEGMENT INFORMATION - Summary of Reportable Segments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Financial information regarding the Company's reportable segments
Net Sales	$ 3,582,890	$ 3,487,450	$ 3,322,249
Selling, Research & Development and Administrative:	582,226	565,783	544,262
Acquisition-related costs	140	480	231
Restructuring initiatives	13,002	45,004	6,597
Curtailment gain related to restructuring initiatives	1,851	0	0
Net unrealized investment gain (loss)	1,713	(2,775)	(3,323)
Depreciation and amortization	(263,784)	(248,593)	(233,706)
Interest Expense	(43,898)	(40,418)	(40,827)
Interest Income	12,101	4,373	2,700
Income before Income Taxes	469,765	374,825	334,704
Capital Expenditures	276,481	312,342	310,427
Total Assets	$ 4,432,278	4,451,890	4,203,458
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Curtailment Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Miscellaneous income (expense), net
Optimization initiative
Financial information regarding the Company's reportable segments
Restructuring initiatives	$ 13,019	45,445	6,224
Prior year initiatives
Financial information regarding the Company's reportable segments
Restructuring initiatives	(17)	(441)	373
Aptar Pharma
Financial information regarding the Company's reportable segments
Net Sales	1,643,152	1,520,993	1,361,256
Aptar Beauty
Financial information regarding the Company's reportable segments
Net Sales	1,225,730	1,267,697	1,222,535
Aptar Closures
Financial information regarding the Company's reportable segments
Net Sales	714,008	698,760	738,458
Operating Segments
Financial information regarding the Company's reportable segments
Net Sales	3,618,480	3,526,161	3,366,522
Adjusted EBITDA	842,422	770,042	679,618
Depreciation and amortization	(260,686)	(244,860)	(227,760)
Capital Expenditures	258,598	332,115	282,822
Total Assets	4,196,204	4,289,912	4,051,310
Operating Segments | Aptar Pharma
Financial information regarding the Company's reportable segments
Net Sales	1,644,012	1,521,837	1,372,449
Cost of Sales (exclusive of depreciation and amortization):	834,595	797,542	709,873
Selling, Research & Development and Administrative:	241,357	221,808	211,101
Other Segment Items:	(1,171)	(990)	(1,340)
Adjusted EBITDA	568,371	502,633	441,622
Restructuring initiatives	589	4,852	0
Depreciation and amortization	(120,429)	(109,366)	(94,396)
Capital Expenditures	148,261	196,083	164,396
Total Assets	2,057,586	2,111,779	1,872,843
Operating Segments | Aptar Beauty
Financial information regarding the Company's reportable segments
Net Sales	1,252,904	1,297,477	1,246,018
Cost of Sales (exclusive of depreciation and amortization):	884,433	922,223	891,619
Selling, Research & Development and Administrative:	183,903	192,831	180,910
Other Segment Items:	(2,515)	(11,073)	(1,881)
Adjusted EBITDA	159,909	163,716	151,887
Restructuring initiatives	8,041	20,683	5,539
Depreciation and amortization	(82,931)	(83,399)	(80,498)
Capital Expenditures	64,571	83,872	74,203
Total Assets	1,392,491	1,412,203	1,398,813
Operating Segments | Aptar Closures
Financial information regarding the Company's reportable segments
Net Sales	721,564	706,847	748,055
Cost of Sales (exclusive of depreciation and amortization):	511,409	507,866	560,300
Selling, Research & Development and Administrative:	89,913	87,930	92,697
Other Segment Items:	(1,456)	(729)	(648)
Adjusted EBITDA	114,142	103,693	86,109
Restructuring initiatives	3,835	17,927	1,058
Depreciation and amortization	(57,326)	(52,095)	(52,866)
Capital Expenditures	45,766	52,160	44,223
Total Assets	746,127	765,930	779,654
Intersegment
Financial information regarding the Company's reportable segments
Net Sales	(35,590)	(38,711)	(44,273)
Intersegment | Aptar Pharma
Financial information regarding the Company's reportable segments
Net Sales	(860)	(844)	(11,193)
Intersegment | Aptar Beauty
Financial information regarding the Company's reportable segments
Net Sales	(27,174)	(29,780)	(23,483)
Intersegment | Aptar Closures
Financial information regarding the Company's reportable segments
Net Sales	(7,556)	(8,087)	(9,597)
Corporate & Other
Financial information regarding the Company's reportable segments
Adjusted EBITDA	(67,498)	(62,320)	(62,930)
Restructuring initiatives	537	1,542	0
Depreciation and amortization	(3,098)	(3,733)	(5,946)
Capital Expenditures	23,630	14,729	29,491
Total Assets	236,074	161,978	152,148
Transfer of Corporate Expenditures
Financial information regarding the Company's reportable segments
Capital Expenditures	$ (5,747)	$ (34,502)	$ (1,886)